Abstract: The invention relates to a peptide and retro or retro-inverso peptide thereof, with a length of ?25 amino acid residues, characterized in that the peptide comprises at least one citrulline residue, and exhibits a sequence identity over the whole sequence of the peptide of ?70% compared to human hnRNP A3 protein (SEQ ID No. 1) and uses thereof.

Abstract: The invention relates to a device comprising: i) a sample-receiving unit (20), said sample-receiving unit (20) comprising a cavity (24) for receiving sample material, means (22) for applying pressure in a regulatable and/or controllable fashion to sample material located in the cavity, and an outlet (25), said outlet (25) being disposed and designed in such a way that, by actuating the means (22) for applying pressure in a regulatable and/or controllable fashion, components of the sample material can be transferred from the cavity (24) through the outlet (25) and directly to an analysis unit (30) connectable to the outlet (25); and ii) an analysis unit (30), said analysis unit (30) comprising an inlet (31), a first filter (32), a reservoir (33) and an analysis track (35), said inlet (31) being designed to be connectable to an outlet (25) of the sample-receiving unit (20) such that components of the sample material can be fed from the sample-receiving unit (20) directly to the analysis unit (30), said first fi

Abstract: The present invention refers to the renin/prorenin receptor (RER) signal transduction pathway and, in particular, to the role of promyelocytic zinc finger protein (PLZF) and its downstream targets involved in this pathway, e.g. the p85? subunit of phosphatidylinositol-3 kinase (PI3K-p85?). In more detail, the present invention refers to a method for determination of RER activity, e.g. stimulation or inhibition of RER activity, using PLZF activity as a measurement from which RER activity is derived. For the determination of RER activity, use can be made of RER/PLZF protein interaction, PLZF translocation and/or PLZF recruitment. The present invention further refers to a use of said method for identifying RER ligands, e.g. pharmaceutically active agonists or antagonists, as well as for studying undesired side-effects of renin inhibitors.

Abstract: The present invention relates to copper-organic complexes and pharmaceutical compositions containing the same. They can be used especially in the treatment of diseases caused by hyperproliferative cells and, in addition, protect healthy tissue from ionizing radiation. They are prepared by reacting a copper(II) acylate with an organic compound selected from 4-[bis(2-chloroethyl)amino]-D,L-phenyl-alanine (sarcolysine), the hydrochloride thereof, N-(2-furanidil)-5-fluorouracil (tegafur) and aminocarbonylaziridine (leacadin) at acidic to neutral pH in a chloroform/methanol mixture.

Abstract: The invention relates to an apparatus for the uniform distribution of microparticles in a liquid, said apparatus comprising a storage chamber 1 including a suspension of microparticles and liquid, a mixing head 2 for receiving the suspension, and a pump 3 which is connected to the storage chamber 1 and the mixing head 2 for sucking the suspension from the storage chamber 1 into the mixing head 2, said mixing head 2 having at least one well 4 with a flow turbulator 5 and an overflow 6 which is connected to the storage chamber 1 via an opening 7, characterized in that the storage chamber 1 has a pin 14 and/or a rotary inlet 15 and a rotary runback 16 which are connected to the pump 3. The apparatus can be used for the identification, characterization and purification of proteins. The invention is also directed to a method for the uniform distribution of microparticles in a liquid, which method generates a turbulent, quasi-static state.

Abstract: Briefly, the present invention refers to the transcription factors PAX2 and PAX8 expressed in solid tumours and haematologic malignancies, and their utility as a target in immunotherapy and molecular therapy. In more detail, the invention refers to a method for identifying an immunogenic T-cell epitope from PAX2 and/or PAX8. Furthermore, the invention refers to a use of immunogenic T-cell epitopes, e.g. identified by said method, and their use as targets for the recognition by targeting means, e.g. T-cells or antibodies. The invention also refers to peptides representing immunogenic T-cell epitopes and their uses for the preparation of a pharmaceutical composition for immunotherapy of PAX2 and/or PAX8 expressing malignancies.

Abstract: The invention relates to a device to produce mechanical oscillations in a research object using magnetic resonance elastography (MRE) with a membrane that can be set into periodic motion (312) and a transmission element (4, 400) for the transmission of periodic motion of the membrane (312) onto the research object (1), whereby the membrane (312) is connected to the transmission element (4, 400) by means of a mounting medium (311, 320, 321, 322) in such a way that periodic motion of the membrane is transmitted over the mounting medium (311, 320, 321, 322) to the transmission element (4, 400). A second aspect relates to the invention of a device with a step motor to generate periodic motion and a transmission element for the transmission of the periodic motion of the step motor to the research object in order to generate mechanical oscillation therein.

Abstract: The invention relates to new uses of soluble CEACAM6 or CEACAM8, or substances that are specific to soluble CEACAM8. Another object of the invention concerns the use of CEACAM1-specific and/or CEACAM6-specific compounds for apoptosis prevention in-vitro. The invention also relates to a method for screening compounds, which prevent apoptosis and a method for preventing apoptosis in human granulocytes.

Abstract: The invention relates to a method of peptide sequencing from peptide fragment mass data, wherein a plurality of candidate peptide sequences are determined comprises the steps of: calculating peptide fragment masses, searching a plurality of peak data for masses matching said calculated peptide fragment masses, annotating all permutations of said peak data with amino acid sequences that correspond to the calculated peptide fragment masses, extending said potential sequences to resulting masses with additional matching masses, extending stepwise additions until the resulting masses correspond to parental peptide masses or said parental peptide masses minus the mass of water, and identifying at least one peptide sequence by deleting sequences that can not be extended to endpoints of said parental peptide masses, and deleting identical sequences generated.

Abstract: The invention relates to an analysis method for determining a functional parameter of an organ of a human or animal individual by measuring the 13CO2 content in the air exhaled by the individual to which a substrate has been administered the reaction of which in the body of the individual enriches the air exhaled by the individual with 13CO2. The method is characterized by using a measuring device, the maximum reaction rate of the substrate in the body of the individual being determined via a change of the measured 13CO2 content in the air exhaled by the individual using zero-order enzyme kinetics. The invention also relates to an aqueous methacetin solution for use in said analysis method, the pH of the solution being greater 7.0. The invention also relates to a face mask (1) for use in the inventive method for separating the exhaled air from the air inhaled by an individual. Said face mask comprises a face mask body (2) and an air cushion (3) encircling the face mask body.

Abstract: Fibroblast-like cells obtained from heart muscle biopsies, which are CD90 negative, CD105 positive, CD117 negative and/or CD166 positive as well as cell preparations of such cells for therapy of heart diseases, as well as a method for providing the latter. The cells are characterized by a good cultivability in cell culture. Furthermore a method for obtaining the cells and cell preparations according to the invention are disclosed.

Abstract: The present invention refers to a method of infiltrating enamel for the prevention and/or treatment of carious lesions comprising (a) exposing an enamel area to a conditioner comprising hydrochloric acid; (b) exposing the conditioned enamel area to an infiltrant; and (c) curing the infiltrant. The present invention further refers to a kit for carrying out the method of infiltrating enamel, which comprises a conditioner comprising hydrochloric acid and an infiltrant comprising at least one low viscous dental resin. Alternatively, the kit comprises ready-to-use means for carrying out the method of infiltrating enamel, e.g. application strips with delivery pads soaked with conditioner or infiltrant. The present invention also refers to a method for identifying an infiltrant by calculation of the penetration coefficient, and to an infiltrant identified by the method having a penetration coefficient of >50 cm/s or comprising a low viscous light curing resin having a penetration coefficient of >50 cm/s.

Abstract: The invention relates to a composition which comprises 1 to 80% by weight of at least one acid which has a pKa of 2 or less; a protic solvent; a complexing agent for Ca2+ ions; for use as conditioning agent for etching enamel lesions.

Abstract: The present invention relates to a sheet or tubular structure consisting of biocompatible material, which is elastic and comprises at least one biologically active substance in at least one region and to a sheet or tubular structure, which comprises at least one biologically active substance release-modifying agent in at least one region as well as an implant covered at least partially by the sheet or tubular structure of the invention. The present invention further provides a method and an apparatus for producing, and preferably customizing and/or optimizing, the sheet or tubular structure of the invention. The sheet or tubular structure of the invention can be customized/optimized before implantation in the operating room.

Abstract: The invention relates to the use of substances which are specific to CEACAM8 for the manufacture of a medicament for the prophylactic or therapeutic treatment of human autoimmune diseases and/or gout. Another object of the invention concerns the use of CEACAM8-specific substances for apoptosis induction in-vitro. The invention also relates to a method for screening substances which induce apoptosis and a method for inducing apoptosis in human granulocytes.

Abstract: The present invention refers to a method of infiltrating enamel, in particular for the prevention and/or treatment of carious lesions. Said method of infiltrating enamel comprises the steps of (a) exposing an enamel area to be infiltrated to a conditioner comprising hydrochloric acid; (b) exposing the enamel area conditioned in step (a) to an infiltrant comprising at least one low viscous dental resin; and (c) curing the infiltrant. The present invention further refers to a kit for carrying out said method.

Abstract: A medicament containing a compound of the following formulas (Ia) and (Ib): wherein Z is selected from the group consisting of a covalent bond, at least one at least divalent hetero atom, a saturated, unsaturated, branched, unbranched and/or cyclic, substituted or unsubstituted hydrocarbon chain, a saturated or unsaturated, branched, unbranched and/or cyclic, substituted or unsubstituted hydrocarbon chain provided with hetero atoms in the chain thereof, or combinations thereof; R?1 to R?4 and R?1 to R?5 independently represent H, at least one hetero atom, especially oxygen, nitrogen or halogens, a saturated, unsaturated, branched, unbranched and/or cyclic, substituted or unsubstituted hydrocarbon chain, a saturated or unsaturated, branched, unbranched and/or cyclic, substituted or unsubstituted hydrocarbon chain provided with hetero atoms in the chain thereof, or combinations thereof; the two cyclopentadienyl rings are optionally linked together via any of residues R?1 to R?5; R1 and R2 independently r

Abstract: Lipid phosphate phosphatase proteins, genes coding for them, vectors and cells comprising them, antibodies directed against them, methods of identifying compounds binding to them and functional interactors as well as to the use of proteins, genes, vectors, cells, interacting compounds and functional interactors for treating neuronal diseases and/or injuries.